The PedsQL Family Impact Module: preliminary reliability and validity.
James W Varni, Sandra A Sherman, Tasha M Burwinkle...
https://pubmed.ncbi.nlm.nih.gov/15450120/Actively Recruiting
Led by Nader Shaikh · Updated on 2026-10-20
1100
Participants Needed
5
Research Sites
12 weeks
Total Duration
Researchers are evaluating treatments for acute otitis media AOM, a common ear infection in young children aged 6 months to under 36 months. The study compares the effects of two antibiotics, amoxicillin and amoxicillin-clavulanate, against placebo treatments to understand how well these options reduce symptom severity. It aims to provide clear evidence on antibiotic use to support better treatment decisions and responsible prescribing. Children participating in the study are randomly assigned to one of four groups receiving amoxicillin, amoxicillin-clavulanate, or matching placebos for each antibiotic. These medications are given orally following pediatric dosing guidelines for AOM. Caregivers complete daily electronic symptom diaries throughout the treatment period to report on their childs symptoms. The study uses a double-blind design, so neither families nor staff know which treatment the child receives. Participants are involved for about 10 days during which daily symptom severity is tracked using caregiver reports. The study also monitors safety outcomes such as diarrhea during this time and follows up for up to 90 days to observe any recurrence of ear or sinus infections. The main measurement is the average daily symptom burden during days 1 to 10. This information helps researchers understand how different treatments impact childrens recovery and guides safer antibiotic use.
CONDITIONS
Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Otitis Media)
J
Jane Luce, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nader Shaikh
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Amoxicillin | Amoxicillin-Clavulanate | Amoxicillin Placebo | Amoxicillin-Clavulanate Placebo |
|---|---|---|---|---|
| What it is | Oral antibiotic (amoxicillin) given in weight-based doses as a standard first-line treatment for acute otitis media (middle ear infection) in young children. | Oral broad-spectrum antibiotic (amoxicillin-clavulanate) given in weight-based doses, targeting AOM bacteria including those resistant to amoxicillin alone. | Placebo matched to amoxicillin, with identical appearance and dosing schedule but no active antibiotic ingredient. | Placebo matched to amoxicillin-clavulanate, with the same dosing schedule and appearance but no active antibiotic. |
| Role in the trial | Assigned as an active antibiotic group to test the effectiveness and safety of amoxicillin for AOM in children. | Assigned as an active antibiotic group to assess whether amoxicillin-clavulanate offers additional benefit or increased risks compared to amoxicillin and placebo. | Control arm for amoxicillin, receiving a matching placebo to measure the drug’s true impact on symptoms and outcomes. | Control arm for amoxicillin-clavulanate, with matching placebo for unbiased evaluation of antibiotic benefits and potential side effects. |
| Primary use | First-line antibiotic therapy for children with acute otitis media to reduce symptom severity and prevent complications. | Broader-spectrum antibiotic therapy for acute otitis media, used when resistance to amoxicillin is suspected or more severe infection is likely. | Inert oral treatment with no active antibiotic, serves as a control to assess the natural course of acute otitis media and the true benefit of active antibiotics. | Inert comparator arm to evaluate the difference between broad-spectrum antibiotic therapy and placebo in AOM management. |
| How it is given or performed | Given by mouth with weight-based dosing for a protocol-specific duration, in alignment with pediatric guidelines for AOM. | Given orally in weight-based doses for a specified duration, consistent with clinical guidelines for AOM. | Matching placebo taken by mouth, using the same frequency and duration as the active drug. | Placebo taken orally with the same schedule as amoxicillin-clavulanate. |
| Evidence status | Amoxicillin has demonstrated moderate reduction in symptom duration and treatment failure rates for AOM in children, as confirmed by meta-analyses and guidelines; some cases resolve without antibiotics. | Amoxicillin-clavulanate provides similar benefits to amoxicillin for most children but may improve outcomes when beta-lactamase–producing bacteria are responsible; has a higher risk of adverse events. | Placebo groups help show that a substantial proportion of children with AOM recover without antibiotics, supporting observation as an option for selected cases. | Placebo groups serve as controls, confirming that not all children require antibiotics for AOM to recover, though risks of complications are higher in some groups. |
| Important risks | Common side effects include diarrhea and rash. Rarely, allergic reactions or severe adverse events can occur. Risks are generally minimal in healthy children but higher in those with allergy history or underlying risk factors. | Has a higher rate of diarrhea and gastrointestinal side effects than amoxicillin alone. Allergic reactions and rare severe adverse events are possible. Use is reserved for specific children due to the side-effect profile. | Minimal risk as this is an inert substance. No antibiotic-related adverse effects expected. Risks are limited to possible allergy to placebo ingredients, which is rare. | No antibiotic side effects, very low risk. Allergy to placebo ingredients remains a theoretical consideration. |
| Important limitations | Antibiotics such as amoxicillin are less effective for viral causes of AOM, may promote resistant bacteria, and are not always needed in mild cases. The benefit is modest in low-risk children, as some improve without antibiotics. | Associated with a greater risk of gastrointestinal side effects and potential for antibiotic resistance. May be overused if not limited to selected cases likely to require broader coverage. | Offers no additional therapeutic benefit against bacterial infection. Some children may develop complications or prolonged symptoms without antibiotics. | No therapeutic effect and no reduction in complications related to untreated bacterial AOM. Used only for research as a comparison condition. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - 10 days
Participants receive either amoxicillin, amoxicillin-clavulanate, or placebo orally. Caregivers complete daily electronic diaries to report symptoms during the treatment period.
Daily symptom diary entries
Duration - 80 days
Participants are monitored for recurrence of acute sinusitis or ear infections and safety outcomes up to 90 days after treatment.
Periodic safety and recurrence assessments
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
James W Varni, Sandra A Sherman, Tasha M Burwinkle...
https://pubmed.ncbi.nlm.nih.gov/15450120/Nader Shaikh, Matthew C Lee, Marcia Kurs-Lasky
https://pubmed.ncbi.nlm.nih.gov/38961165/Stephanie W Hum, Kai J Shaikh, Samar S Musa...
https://pubmed.ncbi.nlm.nih.gov/31561959/James W Varni, Tasha M Burwinkle, Michael Seid...
https://pubmed.ncbi.nlm.nih.gov/14616041/James W Varni, Christine A Limbers, Katie Neighbors...
https://pubmed.ncbi.nlm.nih.gov/20730626/Alejandro Hoberman, Jack L Paradise, Howard E Rockette...
https://pubmed.ncbi.nlm.nih.gov/21226576/Allan S Lieberthal, Aaron E Carroll, Tasnee Chonmaitree...
https://pubmed.ncbi.nlm.nih.gov/23439909/Roderick P Venekamp, Sharon L Sanders, Paul P Glasziou...
https://pubmed.ncbi.nlm.nih.gov/26099233/Nader Shaikh
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor